We have developed an innovative intranasal powder formulation of Naloxone HCl + carrier, delivered via an FDA-approved, gold-standard nasal spray device *. Leveraging our 20+ years of intranasal powder delivery expertise, our ambition is to exceed the bioavailability of existing liquid sprays in the opioid overdose space.

*Indus 3, Courtesy of Aptar Pharma

Our credible management team with expertise in pharma acquisition, licensing, IP, clinical research, product development, regulatory and manufacturing is supported by a heavy weight Scientific Advisory Board.

Our powder form intranasal Naloxone combines proven delivery science, regulatory alignment, and strong market demand. With early-stage IP secured and technical milestones achieved, this platform is positioned to capture meaningful market share and deliver a differentiated, higher-performing alternative to Narcan.

Armed with strong clinical results, we will be running a competitive process to achieve acquisition of our IP and all supportive knowledge & data.